Compare SSP & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSP | CBIO |
|---|---|---|
| Founded | 1878 | 2003 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Broadcasting | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.0M | 340.4M |
| IPO Year | 1996 | N/A |
| Metric | SSP | CBIO |
|---|---|---|
| Price | $3.80 | $19.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.95 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 709.7K | 219.7K |
| Earning Date | 05-07-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,150,585,000.00 | N/A |
| Revenue This Year | $8.34 | N/A |
| Revenue Next Year | N/A | $355.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.91 | $8.72 |
| 52 Week High | $4.98 | $20.58 |
| Indicator | SSP | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 78.57 |
| Support Level | $3.21 | $10.89 |
| Resistance Level | $3.92 | N/A |
| Average True Range (ATR) | 0.25 | 1.57 |
| MACD | 0.01 | 0.80 |
| Stochastic Oscillator | 82.44 | 86.00 |
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.